To test this hypothesis, we used anticancer drugs Dox and CP to induce DNA damage in ACHN and Caki-2 cells and determined whether GLDC knockdown affects cell viabilities in Dox/or CP-treated RCC cells. This evidence concerns the gene GLDC and renal cell carcinoma.